KRYS+147.92%14.3%
NTLA+26.97%14.3%
QURE+198.92%14.3%
RARE+11.52%14.3%
SLNO0.00%14.3%
SRPT+7.63%14.3%
SRRK+52.01%14.3%
As of Jul 10, 2026, 7:14 AM ET
Rare Diseases '25: Gene Therapy & Genetic Med Constituents
| Company | Wgt | Premarket % | 1D % | 10D % | MTD % | YTD % | IranWar % | LibDay % | 1Yr % | Mkt Cap |
|---|---|---|---|---|---|---|---|---|---|---|
Krystal Biotech, Inc.KRYS | 14.3% | -0.20% | -1.11% | -1.83% | -0.09% | 50.58% | 34.68% | 105.10% | 147.92% | $10.94B |
Scholar Rock Holding CorporationSRRK | 14.3% | 0.00% | 3.41% | 5.42% | 9.65% | 31.53% | 30.88% | 78.06% | 52.01% | $6.94B |
Ultragenyx Pharmaceutical Inc.RARE | 14.3% | -1.07% | -0.17% | 12.81% | 6.89% | 50.48% | 47.97% | -2.15% | 11.52% | $3.41B |
uniQure N.V.QURE | 14.3% | 0.87% | 2.28% | -6.14% | -1.53% | 85.88% | 184.58% | 318.83% | 198.92% | $3.03B |
Sarepta Therapeutics, Inc.SRPT | 14.3% | -0.83% | 1.53% | 20.56% | 12.75% | -4.65% | 22.43% | -67.15% | 7.63% | $2.17B |
Intellia Therapeutics, Inc.NTLA | 14.3% | 1.07% | -8.31% | -7.04% | -10.44% | 71.75% | 12.05% | 111.51% | 26.97% | $1.73B |
Soleno Therapeutics, Inc.SLNO | 14.3% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | $1.06B |
| Theme return | — | -0.02% | -0.34% | 3.40% | 2.41% | 47.85% | 45.92% | 67.19% | 68.38% | — |
| Average | 14.3% | -0.02% | -0.34% | 3.40% | 2.46% | 40.80% | 47.51% | 77.74% | 63.57% | $4.18B |
| Median | 14.3% | 0.00% | 0.00% | 0.00% | 0.00% | 50.48% | 30.88% | 78.06% | 26.97% | $3.03B |
| Std Dev | 0.0% | 0.73% | 3.56% | 9.46% | 7.29% | 31.61% | 57.78% | 115.53% | 72.49% | $3.28B |
| Min | 14.3% | -1.07% | -8.31% | -7.04% | -10.44% | -4.65% | 0.00% | -67.15% | 0.00% | $1.06B |
| Max | 14.3% | 1.07% | 3.41% | 20.56% | 12.75% | 85.88% | 184.58% | 318.83% | 198.92% | $10.94B |
| % Positive Tickers | 28.57% | 42.86% | 42.86% | 42.86% | 71.43% | 85.71% | 57.14% | 85.71% |
About this theme
Rare Diseases '25: Gene Therapy & Genetic Med tracks 7 publicly listed stocks in this theme: KRYS, NTLA, QURE, RARE, SLNO, SRPT, SRRK. See the constituent table for details.